Medical Oncology Analysis
Lobular carcinoma of the breast represents approximately 5% to 10% of breast cancers. Lobular carcinoma can often present as a very large tumor whose size is underestimated by the physical examination and the mammographic findings. 1 The small mammographic abnormality (1 cm) with a large palpable mass seen in this patient is not uncharacteristic for lobular carcinoma.
The large primary tumor (greater than 5 cm) makes the patient a candidate for consideration of neo-adjuvant chemotherapy prior to her surgical procedure. Neo-adjuvant chemotherapy would allow an in vivo assessment of the tumor's sensitivity to the chemotherapy. If primary resistance to the Adriamycin/ Cytoxan combination was observed then an alternative treatment with a taxane alone or in combination with another chemotherapeutic agent could have been used after surgery in the adjuvant setting. In addition, successful neo-adjuvant treatment would have reduced the size of primary tumor and the degree of axillary node involvement allowing for more effective surgical removal of disease and making breast conservation feasible for such large tumors. With neo-adjuvant therapy, any micrometastatic systemic tumor may also be decreased. This impairs the formation of resistant cellular clones and the response to angiogenesis and other serum growth factors that are formed after the removal of the primary malignancy. 2 In spite of the potential benefits of neoadjuvant chemotherapy, no survival advantage has been demonstrated in multiple randomized clinical trials. A survival benefit however has been seen in those patients who have been able to achieve a pathologic complete remission documented at the time of surgery. 2 The patient at the surgery was noted to have multiple adverse prognostic features. The primary tumor was greater than 5 cm in diameter (stage III) with involvement of 16 out of 17 axillary lymph nodes suggesting a high probability of metastatic disease and an estimated 5-year survival of less than 50%. 1 At a number of treatment centers, high-risk patients are further staged with bone marrow biopsies performed at the time of surgery. The demonstration of bone marrow involvement with tumor is a stronger predictor than axillary node involvement for the development of systemic metastases. 1 The patient's primary tumor demonstrated an intermediate to high nuclear grade and an elevated S phase suggesting an aggressive biologic nature. The progesterone receptor was absent, which reduces the responsiveness to hormonal agents in estrogen-receptor positive patients. HER-2/neu testing for overexpression was not reported but would be recommended.
After surgery, the patient was started on adjuvant chemotherapy with Adriamycin and Cytoxan receiving 6 cycles of treatment over a 4-month period. The dosages and schedule of the chemotherapy are not available. If the patient's tumor overexpressed HER-2/ neu, the use of an anthracycline, such as Adriamycin, and adequate dose intensity is required for the best possible therapeutic response. 3 The patient was premenopausal at the start of chemotherapy and experienced a chemotherapy-induced menopause. Overall survival appears to be superior in women who develop amenorrhea during adjuvant chemotherapy suggesting some of the benefit derived from treatment is due to the ovarian ablative effects. 4 The patient was then begun on tamoxifen as part of the adjuvant therapy for estrogen-receptor positive tumors. Radiation therapy was administered to complete the local/regional treatment after the modified radical mastectomy.
A disease-free interval of 3 years ensued, after which the patient was noted to have an elevated CA 27,29 and an abnormal bone scan documenting metastatic disease. Unfortunately, the patient now demonstrates progressive metastatic cancer consistent with a failure of her adjuvant chemotherapy and resistance to estrogen-receptor blockade. I assumed other staging studies were also done and found to be negative (eg liver function tests, chest x ray, and computerized axial tomography). After tamoxifen failure in postmenopausal estrogen-receptor positive patients, an aromatase inhibitor (letrozole, exemustine) was the appropriate salvage therapy. 5 If the patient had documentation of liver metastases, the response to an aromatase inhibitor would be so small that an alternative chemotherapy program would have been the preferred therapy. A bisphosphonate such as Aredia should be started concurrently with systemic therapy. Bisphosphonates have been shown to reduce skeletal events in patients with bone metastases from breast cancer (eg pain and compression fractures). 6 At the time of presentation at Block Center for Integrative Cancer Care, the patient had constitutional symptoms with pain, anorexia, fatigue, and a 12-pound weight loss. The patient's physical examination was unremarkable, without evidence of lymphadenopathy, chest wall disease, decreased breath sounds, or hepatomegaly. The patient's initial laboratory evaluation demonstrated an anemia and leukopenia. In the absence of recent exposure to chemotherapy, CBC findings suggest either extensive bone marrow involvement with breast cancer or a chemotherapy-induced myelodysplasia. The patient should receive a full staging evaluation to include a CAT scan of the chest, abdomen, and pelvis, bone scan, metastatic bone survey, brain MRI, bone marrow aspiration, biopsy, and chromosome analysis, cardiac MUGA scan, and HER-2/neu analysis on the primary breast cancer.
The therapeutic approach depends on results of the staging studies and the HER-2/neu analysis. If there was no evidence of visceral organ involvement or rapid constitutional deterioration, the continued use of exemustine would be indicated until there was a clear indication of disease progression. The metastatic bone survey would be reviewed for areas with substantial destruction of bone or risk of impending fracture. Radiation therapy would be considered to those areas of advanced disease for fracture prophylaxis or as an adjunct to pain management.
The patient most likely had widespread aggressive disease including bone marrow involvement and due to her deteriorating status would be best treated by chemotherapy instead of a continued hormonal approach. My treatment choice for patients resistant to anthracyclines would be a taxane, either paclitaxel or docetaxel. If HER-2/neu overexpression had been found on testing, Herceptin would be used concurrently with chemotherapy. This combination of a taxane and Herceptin has been demonstrated to have a synergistic therapeutic effect. 7 Treatment would be administered on a weekly basis to improve tolerance and reduce bone marrow toxicity. 8 The prior Adriamycin exposure may have had an effect on her cardiac function. The ejection fraction on the cardiac MUGA scan would determine any drug-induced impairment that might be adversely influenced by Herceptin exposure. 7 Growth factor support with erythropoietin and G-CSF would be required to prevent further deterioration of the patient's cytopenias.
At the time of disease progression, additional chemotherapeutic agents may be of benefit (eg Gemcitabine, Vinorelbine, liposomal Doxorubicin, or Capecitabine). The response to future therapy, however, would be expected to be low due to the eventual development of multiple drug resistance. At that time investigational agents or hospice care would be considered, given the patient's performance status, disease burden, and personal wishes.
Radiation Oncology and Complementary Care Analysis
The objectives of therapy should be to eliminate unpleasant symptoms, prevent complications, and to improve her quality of life without causing her significant adverse side effects.
The role of radiation is to help control pain and to reduce the risk of a pathological fracture. Radiographs of hot spots on the bone scan should be obtained, with a particular focus on the left femoral head and clavicle, to determine cortical erosion. Radiotherapy to weight-bearing sites will reduce the risk of fracture. Complete cortical bone erosion in the femur may require a prophylactic orthopedic internal fixation, followed by radiotherapy. When radiotherapy is used for pain control, a single fraction of 800 cGy is usually adequate. 1 There is no clinical evidence that continuing her antioxidants will have any adverse effect on her palliative radiotherapy.
Systemic therapy with Pamidronate (which inhibits osteoclast activity) can reduce pain, prevent fractures, and reduce hypercalcemia, and may slow the progression of bone metastases, possibly leading to an increase in survival. 2 A program to reduce fatigue should be considered. Her hemoglobin is only 7.9 g/dl with normocytic red cells. Her iron levels should be checked, as well as her thyroid function. She may benefit from Erythropoietin injections that can reduce fatigue and increase her quality of life. 3 Her symptoms of fatigue and intermittent gastrointestinal disturbance, as well as her psycho-spiritual status, can be helped by Chinese Medicine, such as acupuncture and herbs. Her symptoms suggest a Kidney and Spleen yin deficiency syndrome, with weak Qi, and a relative excess of Liver yang or fire. This syndrome is common in patients who have received chemotherapy and radiation therapy. Chinese herbs and nutrition to boost the Kidney yin and to strengthen the Spleen should be evaluated by a Chinese Medicine herbalist. She should lightly cook her food, since eating a high proportion of raw food will make her Spleen deficiency syndrome worse. Acupuncture to Kidney 3, Spleen 6, and Stomach 36 acupoints should be considered. 4 She should be cautious with exercise that involves severe stress on her skeleton, such as lifting weights. She should consider Qi Gong, since it may reduce her fatigue, reduce psychological stress and depression, and improve pain control, with minimal risk of musculoskeletal damage.
Painful intercourse is clearly detrimental to her quality of life. Under these circumstances, I believe that a natural progesterone cream, used sparingly, will improve her ability to be intimate without any proven risk of promoting cancer progression. Recent studies published in the Journal of the American Medical Association and the Journal of the National Cancer Institute showed an increased risk of breast cancer in women using systemic, synthetic progestins, but not topical natural progesterone. 5 She may also derive psychosocial benefit and improved symptom control from participating in a professional support group. Currently, the evidence suggests that survival of women with advanced metastatic breast cancer is not influenced by expressive and supportive group psychotherapy, but there can be an important impact on quality of life. 6 She may also wish to consider one of the energy therapies (such as healing touch or polarity therapy) that may improve her personal sense of well-being and emotional balance.
Innovative, but clinically unproven, biomolecular therapies may be considered within the context of a clinical trial. These can include various biological response modifiers, such as the many new antiangiogenesis agents. 7 
